CMV screening during pregnancy

Price:

85.00 €

CMV screening during pregnancy is a voluntary, blood-test-based risk assessment that aims to evaluate the risk of a recent cytomegalovirus (CMV) infection in early pregnancy.

In adults, CMV may be mild or go unnoticed, but a primary infection shortly before conception or during the first trimester of pregnancy may, in some cases, affect fetal development, especially the fetal brain and hearing.

The screening includes three tests:

CMV IgG
CMV IgM
CMV IgG avidity

CMV IgG shows previous exposure to the virus. CMV IgM helps assess the possibility of a recent infection. CMV IgG avidity helps clarify whether the infection may have occurred recently or more likely in the past.

The most appropriate time to perform the CMV blood test is in early pregnancy, around 10–11 weeks. Fetal Ultrasound Center recommends combining CMV screening with the Fetal Double Test or OSCAR test so that the blood test result can be assessed together with the detailed 12–13-week ultrasound examination.

If the screening result suggests a possible recent primary CMV infection, the next steps are discussed with the patient individually. If needed, further management may include counseling, consideration of treatment, amniotic fluid testing, fetal neurosonography, and targeted follow-up during pregnancy.

This is not a national screening program in Estonia, but an informed and voluntary opportunity to assess CMV-related risks in early pregnancy.